News & Events

Modern veterinary safety case management is no longer just an operational pharmacovigilance activity—it is a business-critical function that directly affects regulatory compliance, product safety, and market confidence. As veterinary pharmaceutical companies expand into new markets, manage growing product portfolios, and navigate increasingly complex regulatory requirements, the volume and complexity of adverse event reports continue to… View Article …

Pharmaceutical companies invest significant time and resources into medical education, yet many Medical Affairs teams struggle to achieve the impact they expect. Working with large global providers can mean lengthy approval processes, generic educational programmes, limited flexibility, and reduced access to senior scientific experts. As project complexity increases, these challenges can delay delivery, place additional… View Article …

The expectations placed on pharmaceutical companies to deliver high-quality, scientifically accurate, and compliant medical education have never been higher. Healthcare professionals expect relevant, evidence-based educational content, while regulators require that all scientific communication remains balanced, accurate, and aligned with applicable standards. At the same time, Medical Affairs teams are often expected to deliver increasingly complex educational programmes with limited internal resources,… View Article …

Pharmaceutical companies today face increasing pressure to maintain continuous oversight of product safety while meeting ever-evolving global regulatory expectations. A robust signal detection process in pharmacovigilance is no longer limited to reviewing individual case reports—it requires the ability to identify, validate, assess, and act on emerging safety signals using data from multiple sources throughout the… View Article …

Patient journey optimization is rapidly becoming one of the most important strategic priorities for pharmaceutical companies. While many organizations continue to focus primarily on market access, reimbursement, and product availability, they often overlook a critical reality: patients do not experience healthcare through market access pathways. They experience it through diagnosis delays, fragmented care, treatment decisions,… View Article …

Pharmaceutical companies are investing heavily in patient-centricity, yet many still struggle to achieve measurable improvements in patient outcomes. The reason is often surprisingly simple: they do not fully understand the patient journey pharma landscape. Critical barriers to diagnosis, treatment initiation, adherence, and long-term disease management frequently remain hidden, making it difficult to identify where interventions… View Article …

Your medical device is ready for the market. The development phase is complete, the technical documentation is progressing, and your team expects the CE marking process to move forward smoothly. Then comes the most challenging part: clinical evaluation of medical devices. Many manufacturers underestimate how demanding MDR clinical evaluation has become. A weak literature review,… View Article …

Pharmaceutical companies across Europe are increasingly searching for answers to the question: “which vendors support structured product labeling to ePI?” But most organizations are already approaching the problem from the wrong angle. The real challenge is not finding software. The real challenge is surviving the operational complexity that comes with ePI implementation — a challenge… View Article …

Pharmaceutical companies entering the European market often initially struggle to identify a suitably qualified Qualified Person (QP). However, the real challenge begins when they must simultaneously coordinate documentation, importation, GMP compliance, audit readiness, product release timelines, and ongoing GMP consulting support across multiple stakeholders.  In many cases, the process behind obtaining a batch release certificate… View Article …

Many pharmaceutical companies are underestimating how difficult achieving ePI readiness will become once implementation deadlines move closer. What initially appears to be a straightforward compliance initiative often turns into a complex transformation involving regulatory workflows, structured content authoring based on HL7 FHIR standards, multilingual labeling, IT system integration, governance, and lifecycle management. Without a realistic… View Article …

Pharmaceutical companies expanding into Europe often underestimate the complexity of QP batch release once products enter the EU regulatory framework. Under EU GMP Annex 16, every medicinal product batch released to the European market must be certified by a Qualified Person before distribution can legally occur. This requirement applies regardless of whether the product is… View Article …

If you are looking for a medical device regulatory consultant, the situation is usually already serious. Deadlines are approaching, MDR requirements keep expanding, notified body expectations are becoming harder to interpret, and your internal teams are struggling to keep regulatory documentation, vigilance obligations, PRRC responsibilities, and quality systems fully aligned. What initially looked manageable often… View Article …

Companies operating in pharma, medical devices, and other regulated industries cannot afford a weak quality system. Regulatory authorities emphasize that companies must maintain robust and sustainable quality systems to ensure continuous GMP compliance and inspection readiness. When deviations, audit findings, missing documentation, CAPA failures, or inspection observations begin to accumulate, the entire business is at… View Article …

Pharmaceutical companies are under increasing pressure to modernize labeling processes and prepare for electronic product information (ePI) requirements. Yet many organizations searching for “recommended tools for structured product labeling updates” quickly discover that selecting the wrong platform can create costly implementation delays, fragmented workflows, compliance risks, and long-term operational inefficiencies. The challenge is no longer… View Article …

Pharmaceutical companies today are surrounded by data—clinical results, safety signals, real-world evidence—yet some of the most valuable opportunities remain hidden in plain sight. Statins are a striking example. For decades, observations of anti-inflammatory and immune-modulating effects were logged as secondary findings and largely set aside. Today, those same signals are driving serious research into statins’… View Article …

Pharma companies across the EU are facing a growing pressure that many still underestimate. The shift toward ePI requirements is not just another regulatory update, but a fundamental change in how product information must be created, managed and delivered. Under the new legislation, structured electronic product information is becoming a formal requirement, replacing static documents… View Article …